Compare HLIT & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLIT | ABCL |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1996 | 2020 |
| Metric | HLIT | ABCL |
|---|---|---|
| Price | $14.37 | $5.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $14.67 | $8.40 |
| AVG Volume (30 Days) | 4.5M | ★ 7.2M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $42.73 | N/A |
| Revenue Next Year | $18.36 | $21.85 |
| P/E Ratio | $192.86 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $7.80 | $2.75 |
| 52 Week High | $17.68 | $6.79 |
| Indicator | HLIT | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 51.15 |
| Support Level | $9.44 | $3.42 |
| Resistance Level | $15.39 | $5.63 |
| Average True Range (ATR) | 1.16 | 0.55 |
| MACD | -0.31 | -0.11 |
| Stochastic Oscillator | 27.09 | 13.48 |
Harmonic Inc engaged in broadband access solutions that enable broadband operators to more efficiently and effectively deploy high-speed internet for data, voice, and video services for their customers and versatile and high-performance video delivery software, products, system solutions and services that enable its customers to efficiently create, prepare, store, playout and deliver a full range of high-quality broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets, and smartphones. It has two segments, Broadband which provides broadband access solutions and related services, and Others; and Video business provides video processing and production and playout solutions and services, and Others.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.